V
Vaishakhi Trivedi
Researcher at Tata Memorial Hospital
Publications - 12
Citations - 486
Vaishakhi Trivedi is an academic researcher from Tata Memorial Hospital. The author has contributed to research in topics: Lung cancer & Pemetrexed. The author has an hindex of 5, co-authored 11 publications receiving 282 citations. Previous affiliations of Vaishakhi Trivedi include Cancer Research Institute & Homi Bhabha National Institute.
Papers
More filters
Journal ArticleDOI
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
Vanita Noronha,Vijay Patil,Amit Joshi,Nandini Menon,Anuradha Chougule,Abhishek Mahajan,Amit Janu,Nilendu Purandare,Rajesh Kumar,Sucheta More,Supriya Goud,Nandkumar Kadam,Nilesh Daware,Atanu Bhattacharjee,Srushti Shah,Akanksha Yadav,Vaishakhi Trivedi,Vichitra Behel,Amit Dutt,Shripad Banavali,Kumar Prabhash +20 more
TL;DR: Adding pemetrexed and carboplatin chemotherapy to gefitinib significantly prolonged PFS and OS but increased toxicity in patients with NSCLC.
Journal ArticleDOI
Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations
Kanika Bajaj Pahuja,Thong T. Nguyen,Bijay S. Jaiswal,Kumar Prabhash,Tarjani M. Thaker,Kate Senger,Subhra Chaudhuri,Noelyn M. Kljavin,Aju Antony,Sameer Phalke,Prasanna Kumar,Marco Mravic,Eric Stawiski,Derek Vargas,Steffen Durinck,Ravi Gupta,Arati Khanna-Gupta,Sally E. Trabucco,Ethan Sokol,Ryan J. Hartmaier,Ashish Singh,Anuradha Chougule,Vaishakhi Trivedi,Amit Dutt,Vijay Patil,Amit Joshi,Vanita Noronha,James Ziai,S D Banavali,Vedam L. Ramprasad,William F. DeGrado,Raphael Bueno,Natalia Jura,Somasekar Seshagiri +33 more
TL;DR: Structural modeling and analysis showed that the TMD/JMD mutations function by improving the active dimer interface or stabilizing an activating conformation, and it was found that HER2 G660D employed asymmetric kinase dimerization for activation and signaling.
Journal ArticleDOI
Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer
Anuradha Choughule,Richa Sharma,Richa Sharma,Vaishakhi Trivedi,Vaishakhi Trivedi,Abhishek Thavamani,Abhishek Thavamani,Vanita Noronha,Amit Joshi,Subhash Desai,Pratik Chandrani,P Sundaram,S Utture,Nirmala A. Jambhekar,S. Gupta,Jyotirmoi Aich,Kumar Prabhash,Amit Dutt +17 more
TL;DR: Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer.
Journal ArticleDOI
Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis.
Shruti Kate,Anuradha Chougule,Amit Joshi,Vanita Noronha,Vijay Patil,Rohit Dusane,Leena Solanki,Priyanka Tiwrekar,Vaishakhi Trivedi,Kumar Prabhash +9 more
TL;DR: Uncommon EGFR mutations constitute a heterogeneous group, hence, it is imperative to understand each subgroup more to define optimal treatment, and it was observed that TKI sensitive/TKI insensitive dual mutations had a superior OS of 28.2 months.
Journal ArticleDOI
Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C).
Vanita Noronha,Amit Joshi,Vijay Patil,Anuradha Chougule,Abhishek Mahajan,Amit Janu,Nilendu Purandare,Rajiv Kumar,Sucheta More,Supriya Goud,Nandkumar Kadam,Nilesh Daware,Srushti Shah,Akanksha Yadav,Amit Dutt,Vaishakhi Trivedi,Vichitra Behel,Shripad Banavali,Kumar Prabhash +18 more
TL;DR: Standard first-line therapy for EGFR mutant advanced non-small cell lung cancer (NSCLC) is an EGFR-directed oral TKI, but whether adding pemetrexed-carboplatin to Oral TKI treatment with EGFR antagonists is evaluated.